Items tagged with Drug-resistant TB
New TB treatment drug gets mixed reaction (post)
The University of Cape Town's (UCT) head of Pulmonology division, Professor Keertan Dheda, says he is less optimistic about the cocktail of drugs for drug-resistance TB.
Xpert use reduced wait for treatment, study shows, but health system, patient challenges remain barriers to full benefits (post)
The demand for, and the promise of, quick accurate tools to diagnose tuberculosis, and to discover resistance to basic TB treatments, are based on a simple and seemingly irrefutable premise. Such tools, it has been pointed out, make early and effective treatment possible, benefiting both patients and public with faster and more frequent cures, and lowering transmission.
Treating MDR-TB increased risk of acquired resistance to second-line drugs (post)
The treatment of multidrug-resistant tuberculosis significantly increases the risk of acquired resistance to second-line drugs and upgrading the condition to extensively drug-resistant tuberculosis, according to data from a new study.
New hope for MDR-TB patients (post)
5 August 2014 - The USAID-supported Promoting Quality of Medicines (PQM) Program in collaboration with the Global Drug Facility (GDF) has helped attain WHO Pre-Qualification Program (PQP) approval for two important second-line TB drug products. The prequalification of Capreomycin and Levoflaxacin Active Pharmaceutical Ingredients (APIs) is a significant win in the global fight against TB. This new development will save many more lives from multi-drug resistant TB (MDR-TB) by increasing the quality and availability of TB medicines and also bringing about a reduction in price. These quality assured drugs are available through the Global Drug Facility (GDF) to countries to support their fight against MDR-TB.
Use of drug susceptibility testing to select therapy improves treatment outcomes in patients with MDR- and XDR-TB (post)
New research published in the online edition of Clinical Infectious Diseases supports World Health Organization (WHO) recommendations for the use of drug susceptibility testing to select drugs for the treatment of drug-resistant tuberculosis. Drug susceptibility testing for ethambutol, pyrazinamide and second-line anti-tuberculosis (TB) treatment was shown to provide clinically useful information for the selection of treatment regimens for multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB). The chances of treatment success were increased between 1.7 and 4.6-fold when susceptibility testing showed that the use of an individual agent was appropriate.
Rapid MDR-TB test improved clinical outcomes (post)
A rapid molecular diagnostic test significantly reduced the time to treatment initiation in patients with multidrug-resistant tuberculosis, new data suggest.
Drug efficacious in MDR-TB (post)
A tuberculosis (TB) drug with a questionable safety profile increased the rate of sputum culture conversion in people with multidrug-resistant (MDR) disease, researchers reported.
FDA approval of bedaquiline — the benefit–risk balance for drug-resistant tuberculosis (post)
Bedaquiline was approved by the Food and Drug Administration (FDA) at the end of 2012 for the treatment of adults with multidrug-resistant pulmonary tuberculosis for whom an effective treatment regimen is not otherwise available (1). One complexity facing the FDA in reviewing the bedaquiline marketing application was that in one of the phase 2 studies, there were more deaths among patients who had bedaquiline added to a background antimycobacterial drug regimen than among those who had placebo added to the same regimen, despite relatively clear evidence of bedaquiline's efficacy in clearing Mycobacterium tuberculosis from sputum. Given this imbalance in mortality, the approval of bedaquiline has appeared paradoxical to some (2). But marketing applications that are reviewed by the FDA often rely on complex risk–benefit evaluations. (The 120-week final results of the aforementioned phase 2 study are reported by Diacon et al. in this issue of the Journal [pages 723–732]; the marketing application, however, contained only efficacy data that were available at week 72.)
Acquired rifampicin resistance more likely in HIV-coinfected patients (post)
Patients with HIV and tuberculosis were more likely to develop acquired rifampicin resistance when treated with a thrice-weekly tuberculosis treatment compared with patients not coinfected with HIV, according to researchers from the National Institute for Research in Tuberculosis in India.
PNG facing health emergency with discovery of drug-resistant TB (post)
Health authorities in Papua New Guinea say an almost incurable strain of tuberculosis has been found in the capital Port Moresby.
Page 7 of 117 · Total posts: 0
←First 6 7 8 Last→